眼表干细胞同种异体移植术的长期结局
该回顾性干预队列研究纳入因各种病因导致完全性角膜缘干细胞缺乏症、接受至少1次同种异体眼表干细胞移植术且随访≥5年的165眼(110例),平均随访109.22±35.7个月,末次随访时72.7%(120/165眼)实现眼表稳定,62.1%最佳矫正视力改善≥2行。作者认为在适当免疫抑制和失败后重复手术的条件下,同种异体眼表干细胞移植术可提供真正的长期眼表稳定和成功的视力结局。
要点
- 完全性角膜缘干细胞缺乏症行同种异体眼表干细胞移植术后平均随访约9.1年,72.7%(120/165眼)末次随访时眼表稳定。
- 30.9%(51/165眼)需额外眼表干细胞移植手术以维持眼表稳定。
- 末次随访时62.1%眼最佳矫正视力改善≥2行,7.7%无变化,18.6%视力恶化。
核心结论
- 作者认为,在适当免疫抑制和失败后重复手术的条件下,同种异体眼表干细胞移植术可提供真正的长期眼表稳定和成功的视力结局。
研究设计与样本
- 回顾性干预队列研究,单一家三级转诊医院开展。
- 研究人群为存在完全性角膜缘干细胞缺乏症、接受至少1次同种异体眼表干细胞移植术且术后随访≥5年的患者。
- 所有患者于1998年3月至2009年6月接受同种异体眼表干细胞移植术,并接受全身免疫抑制治疗。
- 共纳入110例患者的165眼,平均随访109.22±35.7个月(约9.1年,范围5.2-17.7年)。
主要发现
- 末次随访时72.7%(120/165眼)实现眼表稳定,15.2%(25/165眼)维持改善的眼表,12.1%(20/165眼)出现完全性眼表失败。
- 30.9%(51/165眼)需额外眼表干细胞移植手术以维持稳定眼表。
- 末次随访时62.1%眼最佳矫正视力改善≥2行,7.7%无变化,18.6%视力恶化。
临床怎么用
- 原文结论认为,在适当免疫抑制和失败后重复手术的条件下,同种异体眼表干细胞移植术可提供真正的长期眼表稳定和成功的视力结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the long-term outcomes of ocular surface stem cell allograft transplantation (OSST) in patients with total limbal stem cell deficiency (LSCD) owing to various etiologies with a follow-up ≥ 5 years. DESIGN: Retrospective interventional cohort. METHODS: Setting: Single tertiary referral hospital. STUDY POPULATION: Patients who had (1) presence of total LSCD, (2) surgical treatment with at least 1 allograft OSST procedure, and (3) minimum follow-up ≥ 5 years after OSST. INTERVENTION: All patients underwent allograft OSST from March 1998 to June 2009. All patients received systemic immunosuppression. MAIN OUTCOME MEASURES: Ocular surface stability, best-corrected visual acuity (BCVA). RESULTS: A total of 165 eyes of 110 patients fulfilled the inclusion criteria with a mean follow-up period of 109.22 ± 35.7 months or approximately 9.1 years (range 5.2-17.7 years). Ocular surface stability was achieved in 72.7% (120/165) of eyes at last follow-up, while 15.2% (25/165) maintained an improved ocular surface and 12.1% (20/165) developed total surface failure. Additional OSST surgery was necessary in 30.9% (51/165 eyes) to maintain a stable ocular surface. There was ≥ 2 lines BCVA improvement in 62.1%, no change in 7.7%, and a worsened BCVA in 18.6% at last follow-up. CONCLUSIONS: With proper immunosuppression and repeat procedure in case of failure, allograft OSST can provide true long-term ocular surface stability and successful visual outcomes.
引用
- Movahedan A, Cheung AY, Eslani M, et al. Long-term Outcomes of Ocular Surface Stem Cell Allograft Transplantation. Am J Ophthalmol. 2017. PMID: 29032107. doi:10.1016/j.ajo.2017.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。